Skip to main content
. 2021 Feb 18;20:16. doi: 10.1186/s12944-021-01441-9

Fig. 1.

Fig. 1

Workflow of this study. CON: group of healthy controls; PSO: group of psoriasis patients; IXE: group of ixekizumab-treated psoriasis patients; PC: group of psoriasis patients with coronary heart disease; CV: group of coronary heart disease patients without psoriasis